medroxyprogesterone has been researched along with Hypopituitarism in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duncan, MW; Ho, KK; Hoffman, DM; Nugent, AG; Umpleby, M; Wolthers, T | 1 |
| French, FS; Richman, RA; Underwood, LE; Van Wyk, JJ | 1 |
1 trial(s) available for medroxyprogesterone and Hypopituitarism
| Article | Year |
|---|---|
Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Estradiol; Estrogens; Female; Growth Hormone; Human Growth Hormone; Humans; Hypopituitarism; Insulin-Like Growth Factor I; Leucine; Lipid Metabolism; Medroxyprogesterone; Middle Aged; Progesterone Congeners; Proteins | 2001 |
1 other study(ies) available for medroxyprogesterone and Hypopituitarism
| Article | Year |
|---|---|
Adverse effects of large doses of medroxyprogesterone (MPA) in idiopathic isosexual precocity.
Topics: Adrenal Glands; Adrenal Insufficiency; Adrenocorticotropic Hormone; Body Height; Body Weight; Bone Development; Child, Preschool; Dexamethasone; Female; Gonadotropins, Pituitary; Growth Hormone; Humans; Hypertension; Hypopituitarism; Infant; Male; Medroxyprogesterone; Metyrapone; Pituitary Gland; Puberty, Precocious; Testosterone | 1971 |